Literature DB >> 12378613

Chromosomal aberrations related to metastasis of human solid tumors.

Lun-Xiu Qin1.   

Abstract

The central role of sequential accumulation of genetic alterations during the development of cancer has been firmly established since the pioneering cytogenetic studies successfully defined recurrent chromosome changes in specific types of tumor. In the course of carcinogenesis, cells experience several genetic alterations that are associated with the transition from a preneoplastic lesion to an invasive tumor and finally to the metastatic state. Tumor progression is characterized by stepwise accumulation of genetic alterations. So does the dominant metastatic clone. Modern molecular genetic analyses have clarified that genomic changes accumulate during the development and progression of cancers. In comparison with the corresponding primary tumor, additional events of chromosomal aberrations (including gains or allelic losses) are frequently found in metastases, and the incidence of combined chromosomal alterations in the primary tumor, plus the occurrence of additional aberrations in the distant metastases, correlated significantly with decreased postmetastatic survival. The deletions at 3p, 4p, 6q, 8p, 10q, 11p, 11q, 12p, 13q, 16q, 17p, 18q, 21q, and 22q, as well as the over-representations at 1q, 8q, 9q, 14q and 15q, have been found to associate preferentially with the metastatic phenotype of human cancers. Among of them, the deletions on chromosomes 8p, 17p, 11p and 13p seem to be more significant, and more detail fine regions of them, including 8p11, 8p21-12, 8p22, 8p23, 17p13.3, 11p15.5, and 13q12-13 have been suggested harboring metastasis-suppressor genes. During the past decade, several human chromosomes have been functionally tested through the use of microcell-mediated chromosome transfer (MMCT), and metastasis-suppressor activities have been reported on chromosomes 1, 6, 7, 8, 10, 11, 12, 16, and 17. However, it is not actually known at what stage of the metastatic cascade these alterations have occurred. There is still controversial with the association between the chromosomal aberrations and the metastatic phenotype of cancer. As the progression of human genome project and the establishment of more and more new techniques, it is hopeful to make clear the genetic mechanisms involved in the tumor metastasis in a not very long future, and provide new clues to predicting and controlling the metastasis.

Entities:  

Mesh:

Year:  2002        PMID: 12378613      PMCID: PMC4656559          DOI: 10.3748/wjg.v8.i5.769

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  113 in total

1.  Loss of heterozygosity at D14S62 and metastatic potential of breast cancer.

Authors:  P O'Connell; K Fischbach; S Hilsenbeck; S K Mohsin; S A Fuqua; G M Clark; C K Osborne; D C Allred
Journal:  J Natl Cancer Inst       Date:  1999-08-18       Impact factor: 13.506

2.  Comparison of DNA gains and losses in primary renal clear cell carcinomas and metastatic sites: importance of 1q and 3p copy number changes in metastatic events.

Authors:  J Gronwald; S Störkel; H Holtgreve-Grez; P Hadaczek; C Brinkschmidt; A Jauch; J Lubinski; T Cremer
Journal:  Cancer Res       Date:  1997-02-01       Impact factor: 12.701

3.  Suppression of human melanoma metastasis following introduction of chromosome 6 is independent of NME1 (Nm23).

Authors:  M E Miele; A De La Rosa; J H Lee; D J Hicks; J U Dennis; P S Steeg; D R Welch
Journal:  Clin Exp Metastasis       Date:  1997-05       Impact factor: 5.150

4.  Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization.

Authors:  H Bissig; J Richter; R Desper; V Meier; P Schraml; A A Schäffer; G Sauter; M J Mihatsch; H Moch
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

5.  LOH analyses in the region of the putative tumour suppressor gene C13 on chromosome 13q13.

Authors:  U Fiedler; W Ehlers; A Meye; S Füssel; G Faller; U Schmidt; M P Wirth
Journal:  Anticancer Res       Date:  2001 Jul-Aug       Impact factor: 2.480

6.  Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome microdissection.

Authors:  X Y Guan; P S Meltzer; W S Dalton; J M Trent
Journal:  Nat Genet       Date:  1994-10       Impact factor: 38.330

7.  A human melanoma metastasis-suppressor locus maps to 6q16.3-q23.

Authors:  M E Miele; M D Jewett; S F Goldberg; D L Hyatt; C Morelli; F Gualandi; P Rimessi; D J Hicks; B E Weissman; G Barbanti-Brodano; D R Welch
Journal:  Int J Cancer       Date:  2000-05-15       Impact factor: 7.396

8.  Genetic analysis of the liver putative tumor suppressor (LPTS) gene in hepatocellular carcinomas.

Authors:  Won Sang Park; Jong Heun Lee; Jik Young Park; Seong Whan Jeong; Min Sun Shin; Hong Sug Kim; Sang Kyu Lee; Shi Nae Lee; Sug Hyung Lee; Chul Geun Park; Nam Jin Yoo; Jung Young Lee
Journal:  Cancer Lett       Date:  2002-04-25       Impact factor: 8.679

9.  Comparative genomic hybridization reveals a specific pattern of chromosomal gains and losses during the genesis of colorectal tumors.

Authors:  T Ried; R Knutzen; R Steinbeck; H Blegen; E Schröck; K Heselmeyer; S du Manoir; G Auer
Journal:  Genes Chromosomes Cancer       Date:  1996-04       Impact factor: 5.006

10.  Chromosome 8 Losses in Colorectal Carcinoma: Localization and Correlation With Invasive Disease.

Authors: 
Journal:  Mol Diagn       Date:  1997-03
View more
  12 in total

1.  ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease.

Authors:  Rainer Kuefer; Kathleen C Day; Celina G Kleer; Michael S Sabel; Matthias D Hofer; Sooryanarayana Varambally; Christoph S Zorn; Arul M Chinnaiyan; Mark A Rubin; Mark L Day
Journal:  Neoplasia       Date:  2006-04       Impact factor: 5.715

Review 2.  Molecular determinants of lung cancer metastasis to the central nervous system.

Authors:  Timothy G Whitsett; Landon J Inge; Harshil D Dhruv; Philip Y Cheung; Glen J Weiss; Ross M Bremner; Jeffrey A Winkles; Nhan L Tran
Journal:  Transl Lung Cancer Res       Date:  2013-08

3.  The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma.

Authors:  Ning Ren; Lun-Xiu Qin; Hong Tu; Yin-Kun Liu; Bo-Heng Zhang; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2006-02-25       Impact factor: 4.553

4.  Correlation of CT enhancement, tumor angiogenesis and pathologic grading of pancreatic carcinoma.

Authors:  Zhong-Qiu Wang; Jie-Shou Li; Guang-Ming Lu; Xin-Hua Zhang; Zi-Qian Chen; Kui Meng
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

5.  Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination.

Authors:  Steven Christopher Smith; Brian Nicholson; Matthew Nitz; Henry F Frierson; Mark Smolkin; Garret Hampton; Wael El-Rifai; Dan Theodorescu
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

6.  Expression of tumor related genes NGX6, NAG-7, BRD7 in gastric and colorectal cancer.

Authors:  Xiao-Mei Zhang; Xiao-Yan Wang; Shou-Rong Sheng; Jie-Ru Wang; Jiang Li
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

7.  HLA-DRB1 allele polymorphisms in genetic susceptibility to esophageal carcinoma.

Authors:  Jun Lin; Chang-Sheng Deng; Jie Sun; Xian-Gong Zheng; Xing Huang; Yan Zhou; Ping Xiong; Ya-Ping Wang
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

8.  miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer.

Authors:  Antonis Giannakakis; Raphael Sandaltzopoulos; Joel Greshock; Shun Liang; Jia Huang; Kosei Hasegawa; Chunsheng Li; Ann O'Brien-Jenkins; Dionyssios Katsaros; Barbara L Weber; Celeste Simon; George Coukos; Lin Zhang
Journal:  Cancer Biol Ther       Date:  2007-11-14       Impact factor: 4.742

9.  A novel cytogenetic abnormality t(7;8)(p11.2:q11.2) and a four-way Philadelphia translocation in an imatinib mesylate-resistant chronic myeloid leukemia patient.

Authors:  Walid Al-Achkar; Abdulmunim Aljapawe; Suher Almedani; Thomas Liehr; Abdulsamad Wafa
Journal:  Oncol Lett       Date:  2012-11-21       Impact factor: 2.967

Review 10.  DLC-1:a Rho GTPase-activating protein and tumour suppressor.

Authors:  Marian E Durkin; Bao-Zhu Yuan; Xiaoling Zhou; Drazen B Zimonjic; Douglas R Lowy; Snorri S Thorgeirsson; Nicholas C Popescu
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.